Drug Trial Radar · NCT01825031
Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy
Last checked: Nov 19, 2026Latest source record: Apr 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,805
Actual
Start
Jun 2013
Primary completion
Mar 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- Anna Griffiths, MRCGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Department for International Development, United Kingdom; Wellcome Trust; Medical Research Council; PENTA Foundation
- First posted
- Apr 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomised controlled trial to investigate three methods to reduce early mortality in adults, adolescents and children aged 5 years or older starting antiretroviral therapy (ART) with severe immuno-deficiency. The three methods are: (i) increasing the potency of ART with a 12 week induction period using 4 antiretroviral drugs from 3 classes (ii) augmented prophylaxis against opportunistic/bacterial infections and helminths for 12 weeks (iii) macronutrient intervention using ready-to-use supplementary food for 12 weeks.
Conditions
- Human Immunodeficiency Virus
Interventions
RaltegravirDrug
400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
FluconazoleDrug
100mg once daily for 12 weeks
AzithromycinDrug
500mg once daily for 5 days
AlbendazoleDrug
a single dose 400mg
IsoniazidDrug
300mg taken immediately in combination with cotrimoxazole
Ready to Use Supplementary FoodDietary supplement
2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortality over the first 24 weeks after starting ARTTime frame: Week 24
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Moi University Clinical Research Centre
Eldoret, Kenya
KEMRI Wellcome Trust Research Programme
Kilifi, Kenya
University of Malawi
Blantyre, Malawi
Joint Clinical Research Centre, Fort Portal
Fort Portal, Uganda
Joint Clinical Research Centre, Gulu
Gulu, Uganda
Joint Clinical Research Centre, Mbale
Mbale, Uganda
Joint Clinical Research Centre, Mbarara
Mbarara, Uganda
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.